AI in Biopharma Halves Development Time

A

Alexander Stiehler's presentation at the Longevity Investors Conference 2024.

Quotes From Source

“Companies using machine learning expect to reduce development timelines.”

Story of claim

AI in biopharma can reduce drug development timelines from 3-4 years to 18-24 months, increasing success rates from 10% to 30%.

  • Goal: Highlight AI's potential to enhance biopharma efficiency.
  • Proof: AI's integration in biopharma accelerates development and boosts drug success rates, offering high returns for investors.
  • Nuances:
    • Biopharma sector likely offers the highest return for investors.
  • Impact on Life: AI-driven efficiency in biopharma can lead to faster availability of new drugs, benefiting patients and healthcare providers.

Investments

  • Price:
  • Time:
  • Effort:

Risks

Dependency on AI may lead to unforeseen errors or reliance issues in drug development.

Get Started 🚀

    Brogevity AI can make mistakes. Check important info.

    Reference Video